CN101048140A - 用于治疗癌症的新药物组合物 - Google Patents
用于治疗癌症的新药物组合物 Download PDFInfo
- Publication number
- CN101048140A CN101048140A CNA2005800369528A CN200580036952A CN101048140A CN 101048140 A CN101048140 A CN 101048140A CN A2005800369528 A CNA2005800369528 A CN A2005800369528A CN 200580036952 A CN200580036952 A CN 200580036952A CN 101048140 A CN101048140 A CN 101048140A
- Authority
- CN
- China
- Prior art keywords
- compositions
- solid dispersion
- pharmaceutical composition
- chemical compound
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (33)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60475304P | 2004-08-27 | 2004-08-27 | |
US60/604,753 | 2004-08-27 | ||
PCT/US2005/030542 WO2006026501A1 (en) | 2004-08-27 | 2005-08-29 | New pharmaceutical compositions for the treatment of cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101048140A true CN101048140A (zh) | 2007-10-03 |
CN101048140B CN101048140B (zh) | 2013-06-19 |
Family
ID=35539162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005800369528A Expired - Fee Related CN101048140B (zh) | 2004-08-27 | 2005-08-29 | 用于治疗癌症的药物组合物 |
Country Status (10)
Country | Link |
---|---|
US (2) | US20060078617A1 (zh) |
EP (1) | EP1796642B1 (zh) |
JP (1) | JP5128948B2 (zh) |
CN (1) | CN101048140B (zh) |
AT (1) | ATE395905T1 (zh) |
CA (1) | CA2578442A1 (zh) |
DE (1) | DE602005007048D1 (zh) |
ES (1) | ES2306216T3 (zh) |
MX (1) | MX2007002398A (zh) |
WO (1) | WO2006026501A1 (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009074019A1 (fr) * | 2007-12-11 | 2009-06-18 | Xiaomin Du | Inhibiteurs de protéinase utiles dans le traitement du cancer |
CN103237458A (zh) * | 2010-10-14 | 2013-08-07 | 雅培股份有限两合公司 | 类姜黄素固体分散体制剂 |
CN103301067A (zh) * | 2012-03-15 | 2013-09-18 | 苏州泽璟生物制药有限公司 | 一种改善吸收性能的固体分散体及其制备 |
CN107661296A (zh) * | 2016-07-27 | 2018-02-06 | 江苏先声药业有限公司 | 一种瑞戈非尼固体分散体及其制备方法 |
CN103301066B (zh) * | 2012-03-15 | 2018-12-07 | 苏州泽璟生物制药有限公司 | 一种改善吸收性能的固体分散体及其制备 |
CN110072526A (zh) * | 2016-08-17 | 2019-07-30 | 西奈山伊坎医学院 | 治疗癌症的激酶抑制剂化合物、组合物和方法 |
CN111991418A (zh) * | 2020-08-29 | 2020-11-27 | 吴国斌 | 一种壳聚糖载体的载药***及其制备方法 |
WO2022120512A1 (zh) * | 2020-12-07 | 2022-06-16 | 天津睿创康泰生物技术有限公司 | 一种高生物利用度的索拉非尼药物组合物及应用 |
WO2023155307A1 (zh) * | 2022-02-21 | 2023-08-24 | 北京睿创康泰医药研究院有限公司 | 一种低服用剂量高药物暴露量的索拉非尼或多纳非尼口服制剂及其应用 |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
ATE556713T1 (de) | 1999-01-13 | 2012-05-15 | Bayer Healthcare Llc | Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer |
US7838541B2 (en) | 2002-02-11 | 2010-11-23 | Bayer Healthcare, Llc | Aryl ureas with angiogenesis inhibiting activity |
EP3581228A1 (en) * | 2003-02-21 | 2019-12-18 | ResMed Pty Ltd | Nasal assembly for delivering breathable gas to a patient |
UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
PT1626714E (pt) * | 2003-05-20 | 2007-08-24 | Bayer Pharmaceuticals Corp | Diarilureias para doenças mediadas por pdgfr |
BR122016015715B8 (pt) * | 2003-07-23 | 2021-05-25 | Bayer Healthcare Llc | composições farmacêuticas de metilamida de ácido 4[4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenóxi)-piridina-2-carboxílico |
MY191349A (en) * | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
CA2581843C (en) * | 2004-09-29 | 2012-05-15 | Bayer Healthcare Ag | Thermodynamically stable form of bay 43-9006 tosylate |
PL1868579T3 (pl) * | 2005-03-07 | 2011-03-31 | Bayer Healthcare Llc | Kompozycja farmaceutyczna zawierająca difenylomocznik podstawiony omega-karboksyarylem do leczenia nowotworu |
MX2008014953A (es) * | 2006-05-26 | 2009-03-05 | Bayer Healthcare Llc | Combinaciones de medicamentos con diarilureas sustituidas para el tratamiento de cancer. |
WO2008008733A2 (en) * | 2006-07-10 | 2008-01-17 | Elan Pharma International Ltd. | Nanoparticulate sorafenib formulations |
US20100120717A1 (en) | 2006-10-09 | 2010-05-13 | Brown Jason W | Kinase inhibitors |
AR062927A1 (es) * | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
KR20090094815A (ko) * | 2006-11-09 | 2009-09-08 | 애보트 게엠베하 운트 콤파니 카게 | 티로신 키나아제 억제제의 경구 투여를 위한 약제 투여형 |
PL2305263T3 (pl) * | 2007-06-07 | 2012-12-31 | Novartis Ag | Stabilizowane amorficzne formy mesylanu imatinibu |
JP2011500647A (ja) * | 2007-10-19 | 2011-01-06 | アボット ゲーエムベーハー ウント カンパニー カーゲー | N−アリール尿素系化合物を含む固体分散体生成物 |
US20090203709A1 (en) * | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor |
WO2009106825A1 (en) * | 2008-02-27 | 2009-09-03 | Cipla Limited | Polymorphs of sorafenib and salts thereof |
WO2010142678A2 (en) * | 2009-06-12 | 2010-12-16 | Ratiopharm Gmbh | Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methyl-pyridine-2-carboxamide |
WO2011076711A2 (en) | 2009-12-23 | 2011-06-30 | Ratiopharm Gmbh | Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methylpyridine-2-carboxamide |
AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
TW201202234A (en) | 2010-06-09 | 2012-01-16 | Abbott Lab | Solid dispersions containing kinase inhibitors |
UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
CA3152557A1 (en) | 2010-10-29 | 2012-05-03 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
KR101923364B1 (ko) | 2010-11-23 | 2018-11-30 | 애브비 인코포레이티드 | 아폽토시스유도제의 염 및 결정형 |
CA2820618C (en) | 2010-11-23 | 2020-04-21 | Steven Elmore | Use of sulfonylbenzamide compounds in the treatment of systemic lupus erythematosus, lupus nephritis, or sjogren's syndrome |
EP2559431A1 (en) | 2011-08-17 | 2013-02-20 | Ratiopharm GmbH | Pharmaceutical composition comprising 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide |
US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
AR096469A1 (es) * | 2013-06-06 | 2015-12-30 | Bayer Pharma AG | Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7235576B1 (en) * | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
EP1578346A4 (en) * | 2001-12-04 | 2007-11-28 | Onyx Pharma Inc | INHIBITORS OF THE RAF-MEK-ERK PATHWAY TO TREAT CANCER |
US20030207872A1 (en) * | 2002-01-11 | 2003-11-06 | Bayer Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US7838541B2 (en) * | 2002-02-11 | 2010-11-23 | Bayer Healthcare, Llc | Aryl ureas with angiogenesis inhibiting activity |
-
2005
- 2005-08-29 JP JP2007533490A patent/JP5128948B2/ja not_active Expired - Fee Related
- 2005-08-29 CA CA002578442A patent/CA2578442A1/en not_active Abandoned
- 2005-08-29 MX MX2007002398A patent/MX2007002398A/es active IP Right Grant
- 2005-08-29 WO PCT/US2005/030542 patent/WO2006026501A1/en active Application Filing
- 2005-08-29 EP EP05791660A patent/EP1796642B1/en not_active Not-in-force
- 2005-08-29 DE DE602005007048T patent/DE602005007048D1/de not_active Expired - Fee Related
- 2005-08-29 AT AT05791660T patent/ATE395905T1/de not_active IP Right Cessation
- 2005-08-29 US US11/212,907 patent/US20060078617A1/en not_active Abandoned
- 2005-08-29 ES ES05791660T patent/ES2306216T3/es active Active
- 2005-08-29 CN CN2005800369528A patent/CN101048140B/zh not_active Expired - Fee Related
-
2011
- 2011-11-23 US US13/303,565 patent/US20120142741A1/en not_active Abandoned
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009074019A1 (fr) * | 2007-12-11 | 2009-06-18 | Xiaomin Du | Inhibiteurs de protéinase utiles dans le traitement du cancer |
CN103237458A (zh) * | 2010-10-14 | 2013-08-07 | 雅培股份有限两合公司 | 类姜黄素固体分散体制剂 |
CN103301067A (zh) * | 2012-03-15 | 2013-09-18 | 苏州泽璟生物制药有限公司 | 一种改善吸收性能的固体分散体及其制备 |
CN103301067B (zh) * | 2012-03-15 | 2018-09-11 | 苏州泽璟生物制药有限公司 | 一种改善吸收性能的固体分散体及其制备 |
CN103301066B (zh) * | 2012-03-15 | 2018-12-07 | 苏州泽璟生物制药有限公司 | 一种改善吸收性能的固体分散体及其制备 |
CN107661296A (zh) * | 2016-07-27 | 2018-02-06 | 江苏先声药业有限公司 | 一种瑞戈非尼固体分散体及其制备方法 |
CN110072526A (zh) * | 2016-08-17 | 2019-07-30 | 西奈山伊坎医学院 | 治疗癌症的激酶抑制剂化合物、组合物和方法 |
CN111991418A (zh) * | 2020-08-29 | 2020-11-27 | 吴国斌 | 一种壳聚糖载体的载药***及其制备方法 |
WO2022120512A1 (zh) * | 2020-12-07 | 2022-06-16 | 天津睿创康泰生物技术有限公司 | 一种高生物利用度的索拉非尼药物组合物及应用 |
WO2023155307A1 (zh) * | 2022-02-21 | 2023-08-24 | 北京睿创康泰医药研究院有限公司 | 一种低服用剂量高药物暴露量的索拉非尼或多纳非尼口服制剂及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101048140B (zh) | 2013-06-19 |
EP1796642A1 (en) | 2007-06-20 |
ES2306216T3 (es) | 2008-11-01 |
US20060078617A1 (en) | 2006-04-13 |
MX2007002398A (es) | 2007-05-15 |
JP2008511686A (ja) | 2008-04-17 |
EP1796642B1 (en) | 2008-05-21 |
DE602005007048D1 (de) | 2008-07-03 |
WO2006026501A1 (en) | 2006-03-09 |
JP5128948B2 (ja) | 2013-01-23 |
US20120142741A1 (en) | 2012-06-07 |
CA2578442A1 (en) | 2006-03-09 |
ATE395905T1 (de) | 2008-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101048140A (zh) | 用于治疗癌症的新药物组合物 | |
JP6560289B2 (ja) | 新たな医薬組成物 | |
JP5017115B2 (ja) | 4−(4−(3−(4−クロロ−3−トリフルオロメチルフェニル)ウレイド)−3−フルオロフェノキシ)ピリジン−2−カルボン酸を含んでなる過剰増殖性疾患の治療のための新規薬剤組成物 | |
JP5304241B2 (ja) | 癌の処置用のオメガ−カルボキシアリール置換ジフェニルウレアを含む医薬組成物 | |
JP5835883B2 (ja) | 被覆錠剤製剤 | |
JP5794650B2 (ja) | 難溶性薬物の溶解性改善製剤 | |
CN110035757B (zh) | 一种奥拉帕尼口服缓控释药物组合物及其用途 | |
CN102917697A (zh) | 用于高剂量的水溶性和吸湿性药物的控释剂型 | |
JP2014510795A (ja) | 経口投与用の単位用量形態物 | |
EP3862318A1 (en) | Porous silica particle composition | |
CN110062628B (zh) | 一种瑞卡帕布口服缓控释药物组合物及其用途 | |
JP2010519201A (ja) | シロスタゾールを含む制御放出製剤及びその製造方法 | |
CN101977593A (zh) | 包含弱碱性药物以及有机酸的给药*** | |
CN1178659C (zh) | 控释活性化合物的药物制剂 | |
JP2011500548A (ja) | マンニトールおよび/または微結晶性セルロースを含むジボテンタン組成物 | |
KR20080076440A (ko) | 실로스타졸의 제어방출 제제 및 그 제조방법 | |
CN101854929A (zh) | 新型制剂 | |
EP2701689B1 (en) | Pharmaceutical compositions of raltegravir, methods of preparation and use thereof | |
CN109803684A (zh) | 用于治疗肝细胞癌的组合疗法 | |
CN1883480A (zh) | 一种含卢帕他定的药物组合物 | |
CA2925960A1 (en) | Pharmaceutical composition comprising capecitabine and cyclophosphamide | |
CN105705166B (zh) | 基于丙酸的控释药物组合物 | |
WO2023284724A1 (zh) | 沙库巴曲缬沙坦钠缓释组合物、其制备方法及应用 | |
BR112021004047A2 (pt) | nova composição farmacêutica de lapatinib e processo para preparar uma nova composição farmacêutica de lapatinib |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1109584 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: BAYER HEALTH CARE COMPANY Free format text: FORMER OWNER: BAYER PHARMACEUTICAL COMPANY Effective date: 20100526 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: CONNECTICUT, UNITED STATES, TO: NEW YORK, U.S.A. |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20100526 Address after: American New York Applicant after: Bayer Healthcare LLC Address before: American Connecticut Applicant before: Bayer Pharmaceutical Corp. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1109584 Country of ref document: HK |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130619 Termination date: 20130829 |